Glioblastoma Multiforme — Expanded Access Programs
Overview
Right2Hope maintains a directory of 31 expanded access programs, clinical trials, and compassionate use pathways listed for Glioblastoma Multiforme. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with glioblastoma multiforme programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 9 programs are currently active or recruiting, with the remaining 22 in other lifecycle stages. Sponsors actively running programs in this area include Northwell Health, Northwestern University, Acerta Pharma BV, Apollomics Inc., Aveta Biomics, Inc., and others.
By recruiting status
Snapshot of where every Glioblastoma Multiforme program currently sits in its lifecycle.
- Active / Recruiting9
- Inactive22
Top sponsors
Organisations running the most Glioblastoma Multiforme programs in the directory.
- Northwell Health2 programs
- Northwestern University2 programs
- Acerta Pharma BV1 program
- Apollomics Inc.1 program
- Aveta Biomics, Inc.1 program
- Baptist Health South Florida1 program
- BPGbio1 program
- Bryan Allen1 program
- Chirag G. Patil1 program
- David Baskin MD1 program
Glioblastoma Multiforme programs (31)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on ST101 for Patients with Advanced Solid Tumors — Sapience Therapeutics
- Study on ACP-196 for Treating Recurrent Glioblastoma Multiforme (GBM) — Acerta Pharma BV
- Phase 2 Study of High-Dose Vitamin C for Treating Glioblastoma Multiforme — Bryan Allen
- Phase I Study of Mebendazole for Treating Brain Tumors in Children — Julie Krystal
- Study on Using Stem Cell Rescue and Chemotherapy for Treating Glioblastoma or Gliosarcoma — Leland Metheny
- Study Comparing Nivolumab and Temozolomide with Temozolomide Alone in Newly Diagnosed Elderly Patients with Glioblastoma — University of Sydney
- Study on New Drug LMP744 for Treating Recurrent Glioblastoma — National Institute of Neurological Disorders and Stroke (NINDS)
- Study on Combining Radiation with Tarlatamab for DLL3 Expressing Tumors — University of Arizona
- Study on Ruxolitinib with Radiation and Temozolomide for Newly Diagnosed Glioblastoma — Baptist Health South Florida
- Study on BPM31510 with Vitamin K1 for Patients with Newly Diagnosed Glioblastoma — BPGbio
- Phase 2 Study of NanO2 Combined with Radiation and Chemotherapy for Newly Diagnosed Glioblastoma — NuvOx LLC
- Study on APL-101 for Treating Advanced Solid Tumors with Specific Genetic Changes — Apollomics Inc.
- Expanded Access Program for GBM Patients with DCVax®-L Vaccine Who Couldn't Join the Original Study — Northwest Biotherapeutics
- Expanded Access to Gallium Maltolate (GaM) for Patients with Relapsed or Hard-to-Treat Glioblastoma — Imaging Biometrics, LLC
- Study on HSV G207 Virus Therapy with Radiation for Children with Recurrent High-Grade Brain Tumors — Pediatric Brain Tumor Consortium
- HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM — David Baskin MD
- Study on NG101m as Additional Treatment for Glioblastoma Patients — NeuGATE Theranostics
- Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma — Northwestern University
- Study on Repeated Targeted Brain Infusions of Bevacizumab (Avastin) for Treating Recurrent Aggressive Brain Tumors — Northwell Health
- Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM — Northwell Health
- Study on the Safety and Effectiveness of Bevacizumab with NaviFUS System for Treating Recurrent Glioblastoma Multiforme — NaviFUS Corporation
- Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma — Neonc Technologies, Inc.
- Study on Pembrolizumab and M032 for Treating Recurrent Malignant Brain Tumors — University of Alabama at Birmingham
- Study on Ribociclib and Everolimus for Treating High-Grade Glioma and DIPG in Children and Young Adults — Nationwide Children's Hospital
- Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Patients with Recurrent Glioblastoma — VBI Vaccines Inc.
- Study on Subventricular Zone and Temozolomide Treatment for Glioblastoma Multiforme — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Treating Recurrent High-Grade Glioma with APG-157 and Bevacizumab — Aveta Biomics, Inc.
- Study on Treating Relapsed or Hard-to-Treat Brain Tumors in Patients Under 22 Years Old — University of Miami
- Study on Anti-PD-1 Immunotherapy and Targeted Radiation for Patients with Recurrent Glioblastoma — Chirag G. Patil
- Study on Dichloroacetate (DCA) for Treating Recurrent Glioblastoma Multiforme (GBM) — University of Florida
- Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma — Northwestern University
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Glioblastoma Multiforme to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.